Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALDX NASDAQ:ANIX NASDAQ:ICCC NASDAQ:MRKR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$1.55+0.6%$1.98$1.07▼$6.18$92.89M1.16981,740 shs840,073 shsANIXAnixa Biosciences$2.73+2.2%$2.83$2.44▼$5.46$89.52M0.64120,494 shs114,297 shsICCCImmuCell$9.88-3.1%$7.46$4.52▼$10.25$92.28M0.529,203 shs25,027 shsMRKRMarker Therapeutics$1.41+1.4%$1.44$0.81▼$4.07$23.18M1.4366,037 shs82,627 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-3.50%-9.71%-14.22%-69.24%-36.20%ANIXAnixa Biosciences-3.26%-9.49%-8.25%-7.93%-1.11%ICCCImmuCell+2.93%+21.72%+27.82%+57.41%+86.13%MRKRMarker Therapeutics0.00%-3.47%-16.27%-7.33%+23.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$1.55+0.6%$1.98$1.07▼$6.18$92.89M1.16981,740 shs840,073 shsANIXAnixa Biosciences$2.73+2.2%$2.83$2.44▼$5.46$89.52M0.64120,494 shs114,297 shsICCCImmuCell$9.88-3.1%$7.46$4.52▼$10.25$92.28M0.529,203 shs25,027 shsMRKRMarker Therapeutics$1.41+1.4%$1.44$0.81▼$4.07$23.18M1.4366,037 shs82,627 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-3.50%-9.71%-14.22%-69.24%-36.20%ANIXAnixa Biosciences-3.26%-9.49%-8.25%-7.93%-1.11%ICCCImmuCell+2.93%+21.72%+27.82%+57.41%+86.13%MRKRMarker Therapeutics0.00%-3.47%-16.27%-7.33%+23.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics 2.00Hold$5.50254.84% UpsideANIXAnixa Biosciences 2.25Hold$8.50211.36% UpsideICCCImmuCell 1.00SellN/AN/AMRKRMarker Therapeutics 2.25Hold$10.00609.22% UpsideCurrent Analyst Ratings BreakdownLatest MRKR, ALDX, ICCC, and ANIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026MRKRMarker Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/8/2026ANIXAnixa Biosciences D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.004/6/2026ICCCImmuCell Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D-)3/31/2026ANIXAnixa Biosciences D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/27/2026MRKRMarker Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/18/2026ALDXAldeyra Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$10.00 ➝ $2.003/17/2026ALDXAldeyra Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy2/24/2026ICCCImmuCell Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$0.70 per shareN/AANIXAnixa Biosciences$210K435.89N/AN/A$0.42 per share6.50ICCCImmuCell$27.64M3.23$0.19 per share52.91$3.22 per share3.07MRKRMarker Therapeutics$3.55M6.62N/AN/A$0.83 per share1.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$33.85M-$0.46N/AN/AN/AN/A-57.34%-36.33%8/6/2026 (Estimated)ANIXAnixa Biosciences-$10.93M-$0.33N/AN/AN/AN/A-70.95%-62.53%5/27/2026 (Estimated)ICCCImmuCell-$1.04M-$0.06N/AN/AN/A-1.82%-1.88%-1.22%N/AMRKRMarker Therapeutics-$12.16M-$0.61N/AN/AN/A-343.03%-73.29%-59.70%N/ALatest MRKR, ALDX, ICCC, and ANIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2026Q2 2026ANIXAnixa Biosciences-$0.10N/AN/AN/AN/AN/A5/15/2026Q1 2026MRKRMarker Therapeutics-$0.18-$0.16+$0.02-$0.16$0.78 million$0.75 million5/14/2026Q1 2026ICCCImmuCell$0.05$0.21+$0.16$0.21$5.40 million$10.36 million5/7/2026Q1 2026ALDXAldeyra Therapeutics-$0.13-$0.06+$0.07-$0.06N/AN/A3/18/2026Q4 2025MRKRMarker Therapeutics-$0.21-$0.04+$0.17-$0.04$0.68 million$1.10 million3/9/2026Q1 2026ANIXAnixa Biosciences-$0.09-$0.08+$0.01-$0.08N/AN/A2/27/2026Q4 2025ALDXAldeyra Therapeutics-$0.14-$0.1074+$0.0326-$0.10$24.25 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/AANIXAnixa BiosciencesN/AN/AN/AN/AN/AICCCImmuCellN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra TherapeuticsN/A2.722.72ANIXAnixa BiosciencesN/A12.1812.18ICCCImmuCell0.244.822.60MRKRMarker TherapeuticsN/A4.798.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%ANIXAnixa Biosciences29.13%ICCCImmuCell13.47%MRKRMarker Therapeutics22.39%Insider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics9.60%ANIXAnixa Biosciences26.40%ICCCImmuCell5.70%MRKRMarker Therapeutics5.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1060.32 million54.53 millionOptionableANIXAnixa Biosciences533.53 million24.68 millionOptionableICCCImmuCell709.05 million8.53 millionNot OptionableMRKRMarker Therapeutics6016.67 million15.72 millionNot OptionableMRKR, ALDX, ICCC, and ANIX HeadlinesRecent News About These CompaniesMARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?May 20 at 1:01 PM | zacks.comMarker Therapeutics Sets Date for 2026 Annual MeetingMay 19 at 10:58 PM | theglobeandmail.comMarker Therapeutics (MRKR) Expected to Announce Quarterly Earnings on ThursdayMay 14, 2026 | americanbankingnews.comMarker Therapeutics (MRKR) price target decreased by 12.83% to 8.02April 9, 2026 | msn.comMARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue EstimatesMarch 18, 2026 | zacks.comMarker Therapeutics Reports Encouraging Phase 1 APOLLO Data and Corporate Developments in Immuno-OncologyMarch 18, 2026 | quiverquant.comQMarker Therapeutics Reports Year-End 2025 Corporate and Financial ResultsMarch 18, 2026 | globenewswire.comMarker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFebruary 18, 2026 | globenewswire.comGood Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell TechnologyJanuary 26, 2026 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR), Pasithea Therapeutics Corp (KTTA) and TransMedics Group (TMDX)January 22, 2026 | theglobeandmail.comMRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to KnowJanuary 21, 2026 | zacks.comMarker Therapeutics, Inc. Common Stock (MRKR)January 9, 2026 | nasdaq.comMARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?January 7, 2026 | zacks.com5 Small Drug Stocks to Buy as Industry Recovery Picks UpJanuary 7, 2026 | zacks.comMarker Therapeutics announces publication on MAR-T cells in pancreatic cancerJanuary 5, 2026 | msn.comBaylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic CancerJanuary 5, 2026 | globenewswire.comHere's Why Marker Therapeutics (NASDAQ:MRKR) Must Use Its Cash WiselyDecember 18, 2025 | finance.yahoo.comHC Wainwright & Co. initiates coverage of Marker Therapeutics (MRKR) with buy recommendationDecember 8, 2025 | msn.comMarker Therapeutics initiated with a buy at HC WainwrightDecember 8, 2025 | msn.comMarker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdatesNovember 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRKR, ALDX, ICCC, and ANIX Company DescriptionsAldeyra Therapeutics NASDAQ:ALDX$1.55 +0.01 (+0.65%) Closing price 04:00 PM EasternExtended Trading$1.56 +0.01 (+0.39%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Anixa Biosciences NASDAQ:ANIX$2.73 +0.06 (+2.25%) As of 04:00 PM EasternAnixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.ImmuCell NASDAQ:ICCC$9.88 -0.32 (-3.14%) Closing price 04:00 PM EasternExtended Trading$9.89 +0.01 (+0.10%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.Marker Therapeutics NASDAQ:MRKR$1.41 +0.02 (+1.44%) Closing price 04:00 PM EasternExtended Trading$1.43 +0.02 (+1.35%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook AI Consolidation Begins: Blackstone & Google Forge an AI Empire The Great AI Rotation: Cashing In on Data Mirum Pharma: A Rare Disease Growth Story to Watch Vertical Aerospace: Pre-Flight Checks Point to a Breakout HIVE Weaponizes Power for an AI Pivot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
